mTOR as Mediator of Insulin Sensitivity Study
Mechanistic Target of Rapamycin (mTOR) as Mediator of Exercise-induced Insulin Sensitivity Study
University of Copenhagen
10 participants
Feb 10, 2022
INTERVENTIONAL
Conditions
Summary
The study investigates the role of mTOR in mediating enhancement of muscle insulin sensitivity following a single bout of exercise. This will be investigated in young healthy male subjects by administering the pharmacological mTOR inhibitor Rapamycin in a crossover blinded experimental setup known to enhance muscle insulin sensitivity following one-legged knee-extensor exercise.
Eligibility
Inclusion Criteria7
- Healthy persons (no known disease) without diabetes in the family
- No use of medications
- Non-smokers
- Men
- Age 22-35 years
- Physical activity level (VO2peak) between 30-50 mL O2/min/kg
- BMI between 18.0 and 25.0
Exclusion Criteria6
- Women
- Physical activity (e.g., running, cycling, fitness, etc.) above 6 hours a week.
- Persons who show signs of metabolic diseases, hematologic diseases, reduced liver function, human immunodeficiency virus (HIV), hepatitis, thyroid diseases or other signs of disease that may affect the outcome of the study or the study subject's wellbeing will be excluded.
- Acute sickness less than 2 weeks prior to study start.
- If disease appears or is identified and/or a need for medication arises after inclusion but before initiation of the study.
- Disease during conclusion of the study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
1 hour of one-legged knee-extensor exercise followed by 4 hours of rest
2 hours of Euglycemic Hyperinsulinemic Clamp
Administration of 800 mg of calcium tablets
Administration of 16 mg of Rapamycin tablets
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05233722